PI3K HDAC Inhibitor CUDC-907 (CUDC907) (CAS: 1339928-25-4) is a small molecule inhibitor of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC), two proteins involved in signal transduction pathways that regulate cell growth, differentiation, and survival. It has been investigated as a potential therapeutic agent for cancer, particularly in the treatment of solid tumors and hematological malignancies.
Chemical name: N-(3-(4-acetyl-3-(4-((1-(4-fluorophenyl)-3-(4-methylpiperazin-1-yl)propan-2-yl)amino)piperidin-1-yl)phenyl)isoxazol-5-yl)-N-methylpropanamide
Molecular formula: C32H41FN6O3
Formula weight: 568.71 g/mol
CAS No: 1339928-25-4
Top ten keywords from Google:
Synonyms:
Health benefits of this product: CUDC-907 has demonstrated potential health benefits in the area of cancer research, particularly in the treatment of solid tumors and hematological malignancies. Its primary mode of action is through the inhibition of PI3K and HDAC, leading to reduced cell proliferation and increased apoptosis.
Potential effects: CUDC-907 has demonstrated efficacy in several preclinical studies in inhibiting the activity of PI3K and HDAC, leading to reduced cell proliferation and increased apoptosis in cancer cells. It also has potential benefits for inducing epigenetic modifications, reducing angiogenesis (the formation of new blood vessels that can support tumor growth), and inhibiting signal transduction pathways that regulate cell survival and proliferation. CUDC-907 works by disrupting various cellular processes that are necessary for cancer cell survival and growth.
Product mechanism: CUDC-907 works by inhibiting the activity of PI3K and HDAC, two proteins involved in intracellular signaling pathways that regulate cell growth, differentiation, and survival. PI3K is involved in the regulation of cell proliferation and survival, while HDAC plays a role in gene expression and epigenetic modification. By inhibiting PI3K and HDAC activities, CUDC-907 can disrupt signal transduction pathways, induce epigenetic modifications, and inhibit key processes necessary for cancer cell survival and growth.
Safety: CUDC-907 has been evaluated in several clinical trials involving hundreds of participants and has been generally well-tolerated. Rare but potential side effects may include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, as well as hematological abnormalities (e.g., decreased white blood cell or platelet counts) and hepatic dysfunction. Patients with liver or kidney disease should exercise caution when taking CUDC-907, as it may affect these conditions. Pregnant or breastfeeding women should avoid using CUDC-907, as its safety in these populations has not been established.
Side effects: Common side effects of CUDC-907 may include gastrointestinal symptoms such as nausea, vomiting, and diarrhea. These symptoms are usually mild or moderate and can be managed with supportive care or dose modifications. Less common but more severe side effects may include bleeding disorders, cardiovascular events, and liver or kidney dysfunction, which may require prompt medical intervention. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.
Dosing information: The optimal dose and dosing regimen of CUDC-907 may vary depending on the patient's condition and treatment goals. In clinical trials, doses ranging from 20 to 120 mg per day have been evaluated for solid tumors and hematological malignancies. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.
Conclusion: PI3K HDAC Inhibitor CUDC-907 (CUDC907) (CAS: 1339928-25-4) is a small molecule inhibitor of PI3K and HDAC, two proteins involved in signal transduction pathways that regulate cell growth, differentiation, and survival. It has been investigated as a potential therapeutic agent for cancer, particularly in the treatment of solid tumors and hematological malignancies. Although it has been generally well-tolerated in clinical trials, it may cause some side effects that should be monitored closely. More research is needed to determine its full potential and efficacy in different patient
